Object:The aim of this 6 week open-label study in outpatients
with major depression was to evaluate the efficacy and safety of
venlafaxine, a serotonine and NA reuptake inhibitor, and also to
investigate the effect on hopelessness and suicide ideation.
Method: The 33 patients who are diagnosed as major depression
by using structured Clinical Interview for DSM-III-R, and who
had given the written informed consent and had Hamilton Rating
Scale for Depression score >16 were included in the study.
Patients recieved venlafaxine 75-300 mg/day. Severity and treatment
response evaluated using rating scales (Hamilton Depression
Scale and Hamilton Anxiety Scale) and Clinical Global
Impression and Clinical Global Improvement administered at
baseline and every two weeksd after the first week, in this 6 weeks
study. Side effects were also recorded at every evaluation.
Severity of hopelessness and suicidality were also evaluatied by
using rating scales (Beck Hopelessness Scale and Suicidal Ideation
Scale) at the begining and at the end of the study.
Results: The positive response was defined as end HAM-D-17< 50% of
pretreatment score, reduction of %6.7, %36.7, %80 and 93.3% of
the patients had HAM-D-17
major depression, venlafaxine, efficacy and safety hopelessness, suicide ideation, anxiety